Mavenclad 10 Mg 10 mg Tablet
PDF Leaflet Revision Date: 10 November 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of highly active relapsing multiple sclerosis in adults.
Dosage (summary)
Cumulative dose of 3.5 mg/kg over 2 years, with 1.75 mg/kg per year.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Immunosuppressive medicines
- Live vaccines
- Interferon-beta
Contraindications
- Hypersensitivity to cladribine
- HIV infection
- Active chronic infections
- Immunocompromised patients
- Active malignancy
- Moderate or severe renal impairment
Common side effects
- Lymphopenia
- Herpes zoster
- Hypersensitivity
- Liver injury
- Rash
Counselling Points
- Monitor lymphocyte counts
- Use effective contraception
- Avoid live vaccines during treatment
Serious warnings
- Serious infections risk
- Malignancy risk
- Liver function monitoring required
Important Disclaimer
The Mavenclad 10 Mg 10 mg Tablet professional information leaflet below is the property of Merck and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
